MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells

Prostate

Volumn 72, Issue 15, 2012, Pages 1659-1668

  Rajabi, Hasan ^a   Ahmad, Rehan ^a   Jin, Caining ^a   Joshi, Maya Datt ^a   Guha, Minakshi ^a   Alam, Maroof ^a   Kharbanda, Surender ^b   Kufe, Donald ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Department of Genus Oncology   (United States)

Author keywords

androgen receptor; androgen independent growth; MUC1 C; prostate cancer; targeted therapy

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; MESSENGER RNA; MICRORNA; MICRORNA 135B; MUCIN 1; ONCOPROTEIN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BINDING ASSAY; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CELL STRAIN LAPC4; CELL STRAIN LNCAP; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CYTOPLASM; DNA BINDING; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANDROGENS; CELL PROLIFERATION; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MOLECULAR TARGETED THERAPY; MUCIN-1; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84867047477     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22519     Document Type: Article

References (51)

1. Kufe D,. Mucins in cancer: Function, prognosis and therapy. Nat Rev Cancer 2009; 9 (12): 874-885.
2. Kufe D,. Targeting the MUC1 oncoprotein: A tale of two proteins. Cancer Biol Ther 2008; 7: 81-84.
3. Li Y, Liu D, Chen D, Kharbanda S, Kufe D,. Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene 2003; 22: 6107-6110.
4. Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D,. MUC1 oncoprotein blocks GSK3β-mediated phosphorylation and degradation of β-catenin. Cancer Res 2005; 65 (22): 10413-10422.
5. Kufe D,. Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol Ther 2009; 8 (13): 1201-1207.
6. Ramasamy S, Duraisamy S, Barbashov S, Kawano T, Kharbanda S, Kufe D,. The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol Cell 2007; 27 (6): 992-1004.
7. Kufe D,. Oncogenic function of the MUC1 receptor subunit in gene regulation. Oncogene 2010; 29 (42): 5663-5666.
8. Ahmad R, Raina D, Joshi MD, Kawano T, Kharbanda S, Kufe D,. MUC1-C oncoprotein functions as a direct activator of the NF-κB p65 transcription factor. Cancer Res 2009; 69: 7013-7021.
9. Ahmad R, Rajabi H, Kosugi M, Joshi M, Alam M, Vasir B, Kawano T, Kharbanda S, Kufe D,. MUC1-C oncoprotein promotes STAT3 activation in an auto-inductive regulatory loop. Sci Signal 2011; 4: ra9.
10. Leng Y, Cao C, Ren J, Huang L, Chen D, Ito M, Kufe D,. Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62. J Biol Chem 2007; 282 (27): 19321-19330.
11. Raina D, Ahmad R, Joshi M, Yin L, Wu Z, Kawano T, Vasir B, Avigan D, Kharbanda S, Kufe D,. Direct targeting of the MUC1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res 2009; 69 (12): 5133-5141.
12. Kirschenbaum A, Itzkowitz SH, Wang JP, Yao S, Eliashvili M, Levine AC,. MUC1 expression in prostate carcinoma: Correlation with grade and stage. Mol Urol 1999; 3 (3): 163-168.
13. Cozzi PJ, Wang J, Delprado W, Perkins AC, Allen BJ, Russell PJ, Li Y,. MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin Exp Metastasis 2005; 22 (7): 565-573.
14. Arai T, Fujita K, Fujime M, Irimura T,. Expression of sialylated MUC1 in prostate cancer: Relationship to clinical stage and prognosis. Int J Urol 2005; 12 (7): 654-661.
15. Andrén O, Fall K, Andersson SO, Rubin MA, Bismar TA, Karlsson M, Johansson JE, Mucci LA,. MUC-1 gene is associated with prostate cancer death: A 20-year follow-up of a population-based study in Sweden. Br J Cancer 2007; 97 (6): 730-734.
16. Garbar C, Mascaux C, Wespes E,. Expression of MUC1 and sialyl-Tn in benign prostatic glands, high-grade prostate intraepithelial neoplasia and malignant prostatic glands: A preliminary study. Anal Quant Cytol Histol 2008; 30 (2): 71-77.
17. Rabiau N, Dechelotte P, Guy L, Satih S, Bosviel R, Fontana L, Kemeny JL, Boiteux JP, Bignon YJ, Bernard-Gallon D,. Immunohistochemical staining of mucin 1 in prostate tissues. In Vivo 2009; 23 (2): 203-207.
18. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR,. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101 (3): 811-816.
19. Rajabi H, Joshi M, Jin C, Ahmad R, Kufe D,. Androgen receptor regulates expression of the MUC1-C oncoprotein in human prostate cancer cells. Prostate 2011; 71 (12): 1299-1308.
20. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, Tepper CG, Evans CP, Kung HJ, deVere White RW,. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci USA 2007; 104 (50): 19983-19988.
21. Rajabi H, Jin C, Ahmad R, McClary C, Kufe D,. Mucin 1 oncoprotein expression is suppressed by the miR-125b oncomir. Genes Cancer 2010; 1 (1): 62-65.
22. Joshi MD, Ahmad R, Raina D, Rajabi H, Bubley G, Kharbanda S, Kufe D,. MUC1 oncoprotein is a druggable target in human prostate cancer cells. Mol Cancer Ther 2009; 8 (11): 3056-3065.
23. Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M, Shimamura T, Shapiro G, Supko J, Kharbanda S, Kufe D,. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther 2011; 10 (5): 806-816.
24. Panchamoorthy G, Rehan H, Kharbanda A, Ahmad R, Kufe D,. A monoclonal antibody against the oncogenic mucin 1 cytoplasmic domain. Hybridoma 2011; 30 (6): 531-535.
25. Li P, Lee H, Guo S, Unterman TG, Jenster G, Bai W,. AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol Cell Biol 2003; 23 (1): 104-118.
26. Wei X, Xu H, Kufe D,. MUC1 oncoprotein stabilizes and activates estrogen receptor α. Mol Cell 2006; 21 (2): 295-305.
27. Mehrotra S, Languino LR, Raskett CM, Mercurio AM, Dohi T, Altieri DC,. IAP regulation of metastasis. Cancer Cell 2010; 17 (1): 53-64.
28. Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P,. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res 2009; 69 (8): 3356-3363.
29. Ostling P, Leivonen SK, Aakula A, Kohonen P, Makela R, Hagman Z, Edsjo A, Kangaspeska S, Edgren H, Nicorici D, Bjartell A, Ceder Y, Perala M, Kallioniemi O,. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res 2011; 71 (5): 1956-1967.
30. Horn G, Gaziel A, Wreschner DH, Smorodinsky NI, Ehrlich M,. ERK and PI3K regulate different aspects of the epithelial to mesenchymal transition of mammary tumor cells induced by truncated MUC1. Exp Cell Res 2009; 315 (8): 1490-1504.
31. Roy LD, Sahraei M, Subramani DB, Besmer D, Nath S, Tinder TL, Bajaj E, Shanmugam K, Lee YY, Hwang SI, Gendler SJ, Mukherjee P,. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 2011; 30 (12): 1449-1459.
32. Zhu ML, Kyprianou N,. Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J 2010; 24 (3): 769-777.
33. Zhang D, He D, Xue Y, Wang R, Wu K, Xie H, Zeng J, Wang X, Zhau HE, Chung LW, Chang LS, Li L,. PrLZ protects prostate cancer cells from apoptosis induced by androgen deprivation via the activation of Stat3/Bcl-2 pathway. Cancer Res 2011; 71 (6): 2193-2202.
34. Peinado H, Olmeda D, Cano A,. Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype ? Nat Rev Cancer 2007; 7 (6): 415-428.
35. Li Y, Ren J, Yu W, Li G, Kuwahara H, Yin L, Carraway KL, Kufe D,. The EGF receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and β-catenin. J Biol Chem 2001; 276: 35239-35242.
36. Li Y, Kuwahara H, Ren J, Wen G, Kufe D,. The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3β and β-catenin. J Biol Chem 2001; 276: 6061-6064.
37. Yamamoto M, Bharti A, Li Y, Kufe D,. Interaction of the DF3/MUC1 breast carcinoma-associated antigen and β-catenin in cell adhesion. J Biol Chem 1997; 272: 12492-12494.
38. Gross M, Liu B, Tan J, French FS, Carey M, Shuai K,. Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene 2001; 20 (29): 3880-3887.
39. Cinar B, Collak FK, Lopez D, Akgul S, Mukhopadhyay NK, Kilicarslan M, Gioeli DG, Freeman MR,. MST1 is a multifunctional caspase-independent inhibitor of androgenic signaling. Cancer Res 2011; 71 (12): 4303-4313.
40. Sun Z, Pan J, Balk SP,. Androgen receptor-associated protein complex binds upstream of the androgen-responsive elements in the promoters of human prostate-specific antigen and kallikrein 2 genes. Nucleic Acids Res 1997; 25 (16): 3318-3325.
41. Li Y, Bharti A, Chen D, Gong J, Kufe D,. Interaction of glycogen synthase kinase 3β with the DF3/MUC1 carcinoma-associated antigen and β-catenin. Mol Cell Biol 1998; 18: 7216-7224.
42. Raina D, Kharbanda S, Kufe D,. The MUC1 oncoprotein activates the anti-apoptotic PI3K/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol Chem 2004; 279: 20607-20612.
43. Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC,. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know ? Endocr Rev 2005; 26 (7): 898-915.
44. Terry S, Yang X, Chen MW, Vacherot F, Buttyan R,. Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer. J Cell Biochem 2006; 99 (2): 402-410.
45. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL,. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 2004; 6 (5): 517-527.
46. Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, Sun Z,. Linking beta-catenin to androgen-signaling pathway. J Biol Chem 2002; 277 (13): 11336-11344.
47. Zhou J, Rajabi H, Kufe D,. MUC1-C oncoprotein is a target for small molecule inhibitors. Mol Pharm 2011; 79 (5): 886-893.
48. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1 (1): 34-45.
49. Scher HI, Sawyers CL,. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23 (32): 8253-8261.
50. Massard C, Fizazi K,. Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res 2011; 17 (12): 3876-3883.
51. Attard G, Richards J, de Bono JS,. New strategies in metastatic prostate cancer: Targeting the androgen receptor signaling pathway. Clin Cancer Res 2011; 17 (7): 1649-1657.